title: Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations.
abstract: Pain is the most frequent and distressing symptom in cancer patients. As part of a worldwide effort to improve the quality of pain control, several clinical guidelines for the management of cancer pain have been published and revised in the last decade. The Japanese Society of Palliative Medicine first published a Japanese clinical guideline for the management of cancer pain in 2000. Since then, many clinical studies concerning cancer pain management have been conducted, new drugs have become available in Japan and the methodology of developing a guideline has been refined. Therefore, we decided to develop a novel clinical guideline. This review paper summarizes the recommendations and the rationales of this new clinical guideline for the pharmacological management of cancer pain. In addition, a short summary of the clinical guideline development process is provided. This new Japanese Society of Palliative Medicine guideline highlights the importance of conducting well-designed studies to identify the best practices in cancer pain management.
authors.affiliation: Department of General Internal Medicine and Palliative Care Team,Teine Keijinkai Hospital, 12-1-40, Maeda 1jyo, Sapporo 006-8558, Japan. ikagoro@pop06.odn.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Shima
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Morita
authors.forename: Miki
authors.initials: M
authors.lastname: Hosoya
authors.forename: Motohiro
authors.initials: M
authors.lastname: Matoba
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D009437:Neuralgia / Q000188:drug therapy; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D059408:Pain Management / Q000379:methods*; D010147:Pain Measurement; D010166:Palliative Care / Q000379:methods / Q000458:organization & administration / Q000592:standards / Q000639:trends; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index
chemical_list: D000700:Analgesics; D000701:Analgesics, Opioid; D000889:Anti-Arrhythmia Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D016194:Receptors, N-Methyl-D-Aspartate
keywords: cancer pain; guideline; nonopioid analgesics; opioid analgesics